Crucell Announces Acquisition of SBL Vaccin AB
SBL is a fully integrated independent Swedish biotechnology company employing 120 people. SBL's main product is Dukoral®, an oral vaccine which offers protection against cholera and is registered in more than 50 countries excluding the US. Dukoral® is also registered in the same countries (excluding the EU and Australia) to protect against ETEC (travelers' diarrhea). Sales have increased by more than 60% since 2004. In 2005 sales exceeded EUR14 million (SEK 125 million).
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.